Galmed Pharmaceuticals Ltd. Annual Report Summary

I’m putting together this plain-English guide to help you understand Galmed Pharmaceuticals’ performance this year. My goal is to break down their complex filings so you can decide if this company fits your investment strategy.

1. What does this company do?

Galmed is a clinical-stage drug developer based in Tel Aviv. They focus on Aramchol, an oral treatment for MASH (a severe form of liver disease). Because they are still in the testing phase, they do not sell any products. Their success depends on hitting clinical milestones and managing their cash carefully rather than growing sales.

2. Financial performance

Galmed does not generate revenue. They lost about $10.3 million in 2025, compared to $7.5 million in 2024. This loss came from $5.2 million in research costs and $5.1 million in general administrative expenses. By the end of 2025, they had an accumulated deficit of $210.8 million. They held $6.2 million in cash, which is the most important number for investors. It tells us how long they can operate before they need more money.

3. Major wins and challenges

Galmed is currently looking for ways to maximize the value of their Aramchol project. They are seeking partners, licensing deals, or a potential buyer for the company. A major challenge is the "going concern" warning in their financial reports. This is a formal notice that they do not have enough cash to fund operations for the next 12 months without finding new funding or a strategic partner.

4. Financial health

Galmed’s financial health is fragile. They rely on selling shares to pay for their operations. They have no debt, but their cash is very limited. Their survival depends entirely on their ability to raise money by selling more shares, which depends on market conditions and their stock price.

5. Key risks

The risks here are significant, as is typical for a small biotech firm:

• Clinical Success: The company’s value rests entirely on their clinical trials. If their drug fails to show success, the company may lose almost all its value.
• Dilution: To cover their $10.3 million annual costs, the company frequently issues new shares. This creates more shares, which reduces your ownership percentage.
• Geopolitical Risk: Being based in Israel, Galmed faces extra risks. Regional conflict could disrupt their trials, operations, or access to funding.
• Going Concern: Auditors have warned that the company’s ongoing losses raise doubts about their ability to stay in business. This is an existential risk if they cannot find a partner or new funding soon.
• Market Volatility: As a small, early-stage stock, Galmed’s price can swing wildly. Investors should be prepared for high volatility and the possibility of losing their entire investment if the company fails to secure a breakthrough or a buyer.

Final Thought for Investors: Galmed is a high-stakes, "all-or-nothing" investment. Because they have no revenue and limited cash, they are essentially a bet on the success of the Aramchol project or the ability to find a corporate partner. Before investing, ask yourself if you are comfortable with the high risk of dilution and the uncertainty regarding their ability to fund operations over the next year.